Lumida
/OMER
⌘K
Omeros Corp

Omeros Corp

OMER
$9.69USD↑+5.10%+0.47 today

MARKET CAP

701.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$9 – $10

52W RANGE

$3
$18

AI Summary

Stalk
StalkMedium

OMER is in a Stage 2 corrective reset within its broader long-term uptrend, and the Post-Capitulation pattern signals exhaustion of forced selling. Price is holding above the 9 and 21 EMAs and testing the 50 DMA after the recent flush low, supporting medium-term bullish posture. Short-term conditions are mixed, with price below resistance at the 21 EMA, so execution is deferred into a pullback or confirmation above intermediate EMAs—Stalk for entries on pullbacks into EMAs or upon acceptance above the 21 EMA.

  • ↑Yartemlia Q1 gross revenue $11.1M, driving cash flow positivity.
  • ↑Novo Nordisk partnership provides $240M upfront plus milestone upside.
  • ↓EMA rejected efficacy data, delaying European market entry for Yartemlia.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company specializing in the development of innovative therapeutic products, particularly in the transplant-associated thrombotic microangiopathy (TATMA) market. They recently launched Yartemlia (narsoplimab) in the U.S. after receiving FDA approval, positioning themselves as a leading player within this niche sector of rare diseases. Omeros is also involved in collaborations, most notably with Novo Nordisk, to expand their pipeline and commercial potential.

Bull says

  • ↑Yartemlia Q1 gross revenue $11.1M, driving cash flow positivity.
  • ↑Novo Nordisk partnership provides $240M upfront plus milestone upside.
  • ↑Permanent J-code and NTAP support broad hospital reimbursement.
  • ↑Strong profitability factors and positive earnings revisions underpin stability.
  • ↑High growth momentum and moderate leverage support expansion potential.
  • ↑Regulatory compliance plan may secure EMA approval on reapplication.

Bear says

  • ↓EMA rejected efficacy data, delaying European market entry for Yartemlia.
  • ↓High volatility and 0.98 short interest signal significant downside risk.
  • ↓Dependence on Yartemlia revenue exposes firm to adoption fluctuations.
  • ↓Operating expenses rising without guaranteed sales may worsen cash burn.
  • ↓Competitive TATMA therapies from AstraZeneca and Alnylam threaten share gains.
  • ↓Negative earnings yield and weak size factor heighten valuation concerns.

Investment themes with OMER

Pharmaceuticals↓ -1.67%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-14-2026neutral

Transcript signals

Bull points

  • We would expect that over time to increase as 340B participation increases.
  • I think it's been quite surprising, frankly, how broadly Yartemlia has been used in the absence of the historical reimbursement already in place.
  • Yartemliya became cash flow positive in the first quarter, despite a mid-January launch, and we expect it to drive company-wide positive cash flow within 18 months.

Bear points

  • I would not expect that to be increased, reaching the 20 percentile. I would be thinking we're going to remain in the teens on that search
  • adjusted net gross loss was or net loss was $17.1 million or 24 cents per share.
  • Net income for the first quarter of 2026 was $56.1 million or 78 cents per share compared to net income of 86.5 million or $1.22 per share in the fourth quarter of 2025.
Read full transcript analysis ›